Vaxart is a biotechnology business based in the US. Vaxart shares (VXRT) are listed on the NASDAQ and all prices are listed in US Dollars. Vaxart employs 109 staff and has a trailing 12-month revenue of around $13.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.88 |
|---|---|
| 52-week range | $0.52 - $1.54 |
| 50-day moving average | $0.71 |
| 200-day moving average | $0.85 |
| Wall St. target price | $4.83 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.45 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.8806 from 2024-09-05
| 1 week (2024-08-30) | 1.58% |
|---|---|
| 1 month (2024-08-07) | 47.78% |
| 3 months (2024-06-07) | 14.17% |
| 6 months (2024-03-07) | -20.67% |
| 1 year (2023-09-07) | 19.65% |
|---|---|
| 2 years (2022-09-07) | -68.88% |
| 3 years (2021-09-07) | 8.72 |
| 5 years (2019-09-06) | 26.38% |
| Revenue TTM | $13.9 million |
|---|---|
| Gross profit TTM | $-80,947,000 |
| Return on assets TTM | -39.68% |
| Return on equity TTM | -91.66% |
| Profit margin | 0% |
| Book value | $0.35 |
| Market Capitalization | $197.2 million |
TTM: trailing 12 months
We're not expecting Vaxart to pay a dividend over the next 12 months.
Vaxart's shares were split on a 1:11 basis on 13 February 2018. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vaxart shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for Vaxart shares which in turn could have impacted Vaxart's share price.
Over the last 12 months, Vaxart's shares have ranged in value from as little as $0.52 up to $1.54. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vaxart's is 0.651. This would suggest that Vaxart's shares are less volatile than average (for this exchange).
Vaxart, Inc. , a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI. 1 and GII. 4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.
Use this calculator to quickly see potential outcomes of your options trades.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.